PTC Therapeutics Financial Statements
NASDAQ: PTCTHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
PTC Therapeutics revenue and earnings
In fiscal 2025, PTC Therapeutics generated $1.73 billion in revenue, up 114.5% from fiscal 2024. Net income was $682.6 million, for a net margin of 39.4% versus a median of -80.0% in the prior 5 years. Operating margin was 50.1%.
Diluted earnings per share came in at $7.78. Over the last 5 fiscal years, PTCT's revenue has grown at a 35.4% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
PTC Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.73B | 806.78M | 937.82M | 698.80M | 538.59M | 380.77M | 306.98M | 264.73M | 194.39M | 82.70M |
| Revenue growth (YoY) | +114.51% | -13.97% | +34.20% | +29.75% | +41.45% | +24.04% | +15.96% | +36.19% | +135.04% | +124.95% |
| Cost of Revenue | — | — | — | — | — | — | 12.13M | 12.67M | 4.58M | 0 |
| Gross Profit | — | — | — | — | — | — | 294.85M | 252.06M | 189.81M | 82.70M |
| Operating Expenses | 863.72M | 1.11B | 1.38B | 1.15B | 913.04M | 812.53M | 548.14M | 380.42M | 258.68M | 214.76M |
| Research & Development | 455.25M | 534.48M | 666.56M | 651.50M | 540.68M | 477.64M | 257.45M | 171.98M | 117.46M | 117.63M |
| Selling, General & Admin | 347.14M | 300.91M | 332.54M | 326.00M | 285.77M | 245.16M | 202.54M | 153.55M | 121.27M | 97.13M |
| Operating Income | 866.93M | -302.57M | -439.50M | -447.41M | -374.44M | -431.77M | -241.16M | -115.69M | -64.29M | -132.06M |
| Other Income (Expense) | -18.09M | 6.54M | 10.13M | -49.21M | -57.88M | 85.19M | 13.72M | 129.00K | -1.28M | -1.21M |
| Pretax Income | 696.62M | -363.12M | -696.11M | -587.49M | -518.34M | -402.93M | -239.93M | -128.11M | -77.67M | -141.54M |
| Income Tax | 13.97M | 176.00K | -69.51M | -28.47M | 5.56M | 35.23M | 11.65M | -29.00K | 1.33M | 569.00K |
| Net Income | 682.64M | -363.30M | -626.60M | -559.02M | -523.90M | -438.16M | -251.58M | -128.08M | -79.00M | -142.11M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | 8.58 | -4.73 | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 |
| EPS (Diluted) | 7.78 | -4.73 | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 |
| Shares Outstanding (Basic) | 79.53M | 76.85M | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.18M | 34.04M |
| Shares Outstanding (Diluted) | 88.31M | 76.85M | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.18M | 34.04M |
| EBITDA | 905.75M | -226.91M | -202.91M | -318.57M | -310.31M | -388.28M | -208.98M | -89.60M | -46.61M | -128.77M |
| Gross Margin | — | — | — | — | — | — | 96.05% | 95.21% | 97.65% | 100.00% |
| Operating Margin | 50.09% | -37.50% | -46.86% | -64.03% | -69.52% | -113.39% | -78.56% | -43.70% | -33.07% | -159.67% |
| Net Margin | 39.44% | -45.03% | -66.81% | -80.00% | -97.27% | -115.07% | -81.95% | -48.38% | -40.64% | -171.83% |
This table shows 10 annual periods of PTC Therapeutics's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow PTCT's reporting calendar. What is a income statement?